We can do all of this work on trying to make sure that we approve biosimilars, but if they're not actually getting prescribed, if we aren't giving FDA the resources to make the case that they should be prescribed, we're going to be spending billions and billions of additional dollars that we don't need to simply because we're continuing to funnel money to the makers of the original product who are in competition with the maker of the biosimilar.
Chris Murphy: “We can do all of this work on trying to make sure that we approve biosimilars, but if they're not actually getting…”
Editor's note · Context
Senator Murphy warns about financial implications if biosimilars are not prescribed.
Share
More from Chris Murphy
This is part of a coordinated, deliberate campaign by the Department of Defense to hide the consequences and the true costs of the Iran war.
I’ve been a vocal critic of Saudi Arabia and the Crown Prince. But, I think it’s important to be here to disagree and be honest and candid about those disagreements.
It’s important to recognize there are things we need to work on together: ending the war in Iran and a pathway to Palestinian statehood.
I plan to see for myself the damage to American facilities, hear from our partners in the Gulf about how this war has hurt their security and their economies, and assess our regional counterterrorism efforts.





